US Biopharmaceuticals: On the Launch Radar: Physician Insights on IONS’ Tryngolza sHTG– quotes & transcript

Research evidence excerpt

US Biopharmaceuticals: On the Launch Radar: Physician Insights on IONS’ Tryngolza sHTG– quotes & transcript

Accessible version

US Biopharmaceuticals

On the Launch Radar: Physician Insights on

IONS’ Tryngolza sHTG– quotes & transcript

Industry Overview

On the Launch Radar: Physician Insights 18 June 2026

As part of our “On the Launch Radar, Physician Insights” series, we hosted a cardiology Equity

expert call with Dr. Andrew Freeman to discuss our recent survey results Ionis’ Tryngolza United States

in sHTG (see report). Overall, our survey, launch comps and KOL feedback all support Biopharmaceuticals

launch upside + attractive peak sales opportunity for APO-C3 class (Ionis’ Tryngolza & Jason M. Gerberry

Arrowhead’s Redemplo). Below, we provide key quotes and transcript (page 2+) from the Research Analyst

call. The webcast replay is available upon request. BofAS+1 646 743 0180

jason.gerberry@bofa.com

Tryngolza efficacy differentiation to key uptake demand Chi M. Fong

“I’m really excited that we have drugs available now, for the first time ever, that ResearchBofAS Analyst

specifically target [acute pancreatitis]” +1 646 855 5264 chi.fong@bofa.com

“the exciting part around [Tryngolza] is really the acute pancreatitis reduction, we really Dina Ramadane

Research Analyst

don't have any drugs that specifically target that … acute pancreatitis is probably one of BofAS

the more miserable things that people go through and that we treat” +1 646 556 0492 dina.ramadane@bofa.com

“Anyone who remains difficult to control… staying over 500… I can't imagine why they Richard Wagner >>

wouldn't want to be on this…Anyone who has had acute pancreatitis and high MLI (UK)

triglycerides, this [Tryngolza] is a no-brainer” +44 20 7995 9925 richard.wagneriii@bofa.com